12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican based regimen either in combination with Cyclosporin A or Tacrolimus

Trial Profile

12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican based regimen either in combination with Cyclosporin A or Tacrolimus

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate mofetil; Mycophenolate sodium; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms ATHENA
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 06 Jun 2018 Results presented at the 2018 American Transplant Congress
    • 06 Jun 2018 Results presented at the 2018 American Transplant Congress
    • 06 Jun 2018 Results assessing the Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen, presented at the 2018 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top